Online ISSN: 2187-2988 Print ISSN: 0911-1794
特定非営利活動法人日本小児循環器学会 Japanese Society of Pediatric Cardiology and Cardiac Surgery
Pediatric Cardiology and Cardiac Surgery 36(3): 223-229 (2020)


免疫グロブリン5%製剤と10%製剤の川崎病に対する治療効果・安全性の比較Comparison of the Safety and Effectiveness of 5% Immunoglobulin and 10% Immunoglobulin for the Treatment of Kawasaki Disease

大津赤十字病院小児科Department of Pediatrics, Otsu Red Cross Hospital ◇ Shiga, Japan

受付日:2019年11月25日Received: November 25, 2019
受理日:2020年3月17日Accepted: March 17, 2020
発行日:2020年10月1日Published: October 1, 2020




結果:両群間で投与前の患者背景に有意差はなかった.初回IVIG不応例は,5%製剤で31例(30%),10%製剤で20例(33%)で有意差を認めなかった(p=0.727).初回IVIG投与から追加IVIG投与までの時間は,10%製剤で有意に短かった(48.8 vs 45.3時間,p=0.004).冠動脈病変(CAL)は5%製剤で1例(1.0%)認めたのみであった.重大な副作用については,両製剤とも認めなかった.


Background: Intravenous immunoglobulin (IVIG) is the mainstay of initial treatment for Kawasaki disease (KD). Previously, 5% immunoglobulin was used for the treatment of patients with KD; however, a 10% immunoglobulin preparation has recently become available.

Purpose: To analyze the safety and effectiveness of treatment with 10% immunoglobulin in patients with KD. Additionally, we sought to determine whether it was possible to shorten the interval between the initial IVIG dose and the second IVIG dose, among the patients who did not respond to the initial IVIG dose (non-responders) in the 10% IVIG group.

Methods: We retrospectively compared the clinical findings of 103 patients who were administered 5% IVIG, and 60 patients who were administered 10% IVIG between January 2015 and May 2019.

Results: The clinical profiles were not significantly different between the 5% and 10% groups. A total of 31 (30%) patients in the 5% group, and 20 (33%) patients in the 10% group, were nonresponsive to the initial IVIG dose, although these differences were not significant (p=0.727). The interval between the initial IVIG dose and the second IVIG dose among the non-responders was significantly shorter in the 10% IVIG group than the 5% IVIG group (48.8 vs 45.4 hours, p=0.004). Only one patient in the 5% group developed coronary artery lesions, and no serious adverse events were observed.

Conclusion: Results showed that 10% immunoglobulin is as safe and effective as 5% immunoglobulin for the treatment of patients with KD, and can provide additional early treatment for non-responders to the initial IVIG dose.

Key words: Kawasaki disease; intravenous immunoglobulin; 10% immunoglobulin; administration time; non-responeders

This page was created on 2020-08-25T16:03:09.347+09:00
This page was last modified on 2020-10-19T11:44:51.000+09:00